Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:ATOS NASDAQ:MIRA NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95$0.83$0.55▼$2.22$11.76M1.48195,180 shs189,908 shsATOSAtossa Genetics$4.96$5.28$3.76▼$19.35$42.71M1.2551,449 shs28,196 shsMIRAMIRA Pharmaceuticals$0.99$1.04$0.90▼$2.45$41.69M1.48112,795 shs34,651 shsTLPHTalphera$0.82$0.81$0.38▼$1.57$42.30M0.79153,434 shs43,878 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%+12.40%+2.16%+18.76%-43.11%ATOSAtossa Genetics0.00%+3.77%-12.98%+17.81%-60.24%MIRAMIRA Pharmaceuticals0.00%+1.64%-5.52%-20.64%-18.69%TLPHTalphera0.00%+2.23%+5.17%-7.45%+61.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95$0.83$0.55▼$2.22$11.76M1.48195,180 shs189,908 shsATOSAtossa Genetics$4.96$5.28$3.76▼$19.35$42.71M1.2551,449 shs28,196 shsMIRAMIRA Pharmaceuticals$0.99$1.04$0.90▼$2.45$41.69M1.48112,795 shs34,651 shsTLPHTalphera$0.82$0.81$0.38▼$1.57$42.30M0.79153,434 shs43,878 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%+12.40%+2.16%+18.76%-43.11%ATOSAtossa Genetics0.00%+3.77%-12.98%+17.81%-60.24%MIRAMIRA Pharmaceuticals0.00%+1.64%-5.52%-20.64%-18.69%TLPHTalphera0.00%+2.23%+5.17%-7.45%+61.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07328.07% UpsideATOSAtossa Genetics 2.40Hold$36.33632.53% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ATLPHTalphera 2.00Hold$3.00268.05% UpsideCurrent Analyst Ratings BreakdownLatest APRE, TLPH, ATOS, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/11/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/30/2026TLPHTalphera Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TLPHTalphera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ATOSAtossa Genetics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$120.00 ➝ $24.003/31/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.003/31/2026APREAprea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $1.203/27/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K40.56N/AN/A$3.36 per share0.28ATOSAtossa GeneticsN/AN/AN/AN/A$3.54 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.22 per shareN/ATLPHTalphera$30K1,410.12N/AN/A$0.36 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)ATOSAtossa Genetics-$34.77M-$3.21N/AN/AN/AN/A-84.91%-72.36%8/11/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.30N/AN/AN/AN/A-140.82%-135.01%6/3/2026 (Estimated)TLPHTalphera-$14.29M-$0.31N/AN/AN/AN/A-92.98%-53.22%8/13/2026 (Estimated)Latest APRE, TLPH, ATOS, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MIRAMIRA PharmaceuticalsN/A-$0.03N/A-$0.03N/AN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 million$0.28 million5/13/2026Q1 2026TLPHTalphera-$0.07-$0.04+$0.03-$0.04N/AN/A5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/A3/23/2026Q4 2025 & Investor DayTLPHTalphera-$0.0750-$0.06+$0.0150-$0.06$0.58 millionN/A3/16/2026Q4 2025APREAprea Therapeutics-$0.38-$0.32+$0.06-$0.32N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AATOSAtossa GeneticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92ATOSAtossa GeneticsN/A4.924.92MIRAMIRA PharmaceuticalsN/A82.1582.15TLPHTalpheraN/A5.305.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%ATOSAtossa Genetics12.74%MIRAMIRA Pharmaceuticals35.16%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%ATOSAtossa Genetics9.80%MIRAMIRA Pharmaceuticals6.65%TLPHTalphera3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million10.70 millionNo DataATOSAtossa Genetics88.61 million7.77 millionOptionableMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableTLPHTalphera1951.90 million50.08 millionOptionableAPRE, TLPH, ATOS, and MIRA HeadlinesRecent News About These CompaniesTalphera (TLPH) CEO Angotti buys $85k in sharesMay 21, 2026 | investing.comTalphera Earnings Call Highlights NEPHRO Trial MomentumMay 19, 2026 | tipranks.comAcusphere (OTCMKTS:ACUS) and Talphera (NASDAQ:TLPH) Head-To-Head ComparisonMay 19, 2026 | americanbankingnews.comTalphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...May 15, 2026 | finance.yahoo.comTalphera Earnings Call Highlights Trial Momentum, RisksMay 14, 2026 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comTalphera Q1 2026 Earnings Call TranscriptMay 13, 2026 | finance.yahoo.comTalphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%May 13, 2026 | seekingalpha.comTalphera (TLPH) Q1 2026 Earnings TranscriptMay 13, 2026 | fool.comTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026May 7, 2026 | prnewswire.comWestPark Capital initiates coverage of Talphera (TLPH) with buy recommendationMay 1, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)March 26, 2026 | theglobeandmail.comTalphera (NASDAQ:TLPH) CEO Acquires $125,852.90 in StockMarch 26, 2026 | insidertrades.comTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026March 25, 2026 | prnewswire.comTalphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 24, 2026 | finanznachrichten.deTalphera, Inc. (TLPH) Analyst/Investor Day TranscriptMarch 24, 2026 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 23, 2026 | prnewswire.comTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026March 18, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Investors Abandoned These 3 AI Stocks Too Early, Says Jeff ClarkBy Bridget Bennett | May 21, 2026APRE, TLPH, ATOS, and MIRA Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.95 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.53%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Atossa Genetics NASDAQ:ATOS$4.96 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.82 -0.14 (-2.90%) As of 05/22/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.MIRA Pharmaceuticals NASDAQ:MIRA$0.99 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.71%) As of 05/22/2026 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Talphera NASDAQ:TLPH$0.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.81 0.00 (-0.26%) As of 05/22/2026 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
